Myelodysplastic Syndrome - Pipeline Review, H2 2016
"Myelodysplastic
Syndrome - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Myelodysplastic Syndrome Pipeline Review, H2 2016,
provides an overview of the Myelodysplastic Syndrome (Oncology)
pipeline landscape.
Myelodysplastic
syndrome (MDS) is a condition that affects the bone marrow and the
blood cells it produces. Myelodysplastic syndromes rarely cause signs
or symptoms in the early stages of the disease. Symptoms include
fatigue, shortness of breath, unusual paleness (pallor) due to
anemia, easy or unusual bruising or bleeding and frequent infections.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Myelodysplastic Syndrome Pipeline Review, H2 2016, provides
comprehensive information on the therapeutics under development for
Myelodysplastic Syndrome (Oncology), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of
key players involved in therapeutic development for Myelodysplastic
Syndrome and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11,
62, 55, 3, 13 and 2 respectively. Similarly, the Universities
portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown
stages comprises 6, 7, 2, 1 and 2 molecules,
respectively.Myelodysplastic Syndrome.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Myelodysplastic Syndrome (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Myelodysplastic
Syndrome (Oncology) by companies and universities/research institutes
based on information derived from company and industry-specific
sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Myelodysplastic
Syndrome (Oncology) therapeutics and enlists all their major and
minor projects.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Myelodysplastic Syndrome (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
Comments
Post a Comment